Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions

This study has been completed.
Information provided by:
Roxane Laboratories Identifier:
First received: March 21, 2011
Last updated: March 22, 2011
Last verified: March 2011

The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fasting conditions.

Condition Intervention
Herpes Nos
Drug: famciclovir

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fasting Conditions

Resource links provided by NLM:

Further study details as provided by Roxane Laboratories:

Primary Outcome Measures:
  • bioequivalence determined by statistical comparison Cmax [ Time Frame: 8 days ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: July 2007
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: famciclovir
    500 mg tablet
    Other Name: FAMVIR

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to famciclovir, penciclovir or any comparable or similar product.
  Contacts and Locations
Please refer to this study by its identifier: NCT01321515

United States, New Jersey
Advanced Biomedical Research, Inc.
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
Roxane Laboratories
Principal Investigator: Benno G Roesch, M.D. Advanced Biomedical Research
  More Information

No publications provided

Responsible Party: Elizabeth Ernst, Executive Director, Drug Regulatory and Medical Affairs, Roxane Laboratories, Inc. Identifier: NCT01321515     History of Changes
Other Study ID Numbers: FAMC-T500-PVFS-1
Study First Received: March 21, 2011
Last Updated: March 22, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 22, 2014